Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence.

Sing A, Reithmeier-Rost D, Granfors K, Hill J, Roggenkamp A, Heesemann J.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16049-54. Epub 2005 Oct 20.

PMID:
16239347
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Plague bacteria target immune cells during infection.

Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O.

Science. 2005 Sep 9;309(5741):1739-41. Epub 2005 Jul 28.

PMID:
16051750
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

LcrV plague vaccine with altered immunomodulatory properties.

Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O.

Infect Immun. 2005 Aug;73(8):5152-9.

PMID:
16041032
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M.

Infect Immun. 2005 Jun;73(6):3598-608.

PMID:
15908389
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.

Philipovskiy AV, Cowan C, Wulff-Strobel CR, Burnett SH, Kerschen EJ, Cohen DA, Kaplan AM, Straley SC.

Infect Immun. 2005 Mar;73(3):1532-42.

PMID:
15731051
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S.

Vaccine. 2004 Sep 3;22(25-26):3348-57.

PMID:
15308359
[PubMed - indexed for MEDLINE]
7.

Protective efficacy of a fully recombinant plague vaccine in the guinea pig.

Jones SM, Griffin KF, Hodgson I, Williamson ED.

Vaccine. 2003 Sep 8;21(25-26):3912-8.

PMID:
12922126
[PubMed - indexed for MEDLINE]
8.

Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Brubaker RR.

Infect Immun. 2003 Jul;71(7):3673-81. Review. No abstract available.

PMID:
12819047
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression.

Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J.

J Exp Med. 2002 Oct 21;196(8):1017-24.

PMID:
12391013
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Yersinia type III secretion: send in the effectors.

Cornelis GR.

J Cell Biol. 2002 Aug 5;158(3):401-8. Epub 2002 Aug 5. Review.

PMID:
12163464
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.

Weeks S, Hill J, Friedlander A, Welkos S.

Microb Pathog. 2002 May;32(5):227-37.

PMID:
12071679
[PubMed - indexed for MEDLINE]
12.

Hijacking and exploitation of IL-10 by intracellular pathogens.

Redpath S, Ghazal P, Gascoigne NR.

Trends Microbiol. 2001 Feb;9(2):86-92. Review.

PMID:
11173248
[PubMed - indexed for MEDLINE]
13.

Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains.

Jones SM, Day F, Stagg AJ, Williamson ED.

Vaccine. 2000 Sep 15;19(2-3):358-66.

PMID:
10930691
[PubMed - indexed for MEDLINE]
14.

LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells.

Lee VT, Tam C, Schneewind O.

J Biol Chem. 2000 Nov 24;275(47):36869-75.

PMID:
10930402
[PubMed - indexed for MEDLINE]
Free Article
15.

V antigen of Yersinia pestis inhibits neutrophil chemotaxis.

Welkos S, Friedlander A, McDowell D, Weeks J, Tobery S.

Microb Pathog. 1998 Mar;24(3):185-96.

PMID:
9514641
[PubMed - indexed for MEDLINE]
16.

Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092.

Welkos SL, Friedlander AM, Davis KJ.

Microb Pathog. 1997 Oct;23(4):211-23.

PMID:
9344782
[PubMed - indexed for MEDLINE]
17.

Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.

Nedialkov YA, Motin VL, Brubaker RR.

Infect Immun. 1997 Apr;65(4):1196-203.

PMID:
9119451
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Yersinia pestis--etiologic agent of plague.

Perry RD, Fetherston JD.

Clin Microbiol Rev. 1997 Jan;10(1):35-66. Review.

PMID:
8993858
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague.

Motin VL, Nedialkov YA, Brubaker RR.

Infect Immun. 1996 Oct;64(10):4313-8.

PMID:
8926104
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM.

Infect Immun. 1996 Nov;64(11):4580-5.

PMID:
8890210
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk